Bio Pharma Dive

MARCH 2, 2023

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

Gene Editing 304

Gene Editing In-Vivo Gene Drugs 304

Bio Pharma Dive

MARCH 20, 2024

The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.

In-Vivo 180

In-Vivo 180

pharmaphorum

OCTOBER 28, 2024

Discover the latest advancements in cell therapy with the next generation of innovative treatments that are revolutionising healthcare. Explore the future of medicine today.

In-Vivo 105

In-Vivo Medicine 105

Bio Pharma Dive

OCTOBER 7, 2024

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

Gene Editing 187

Gene Editing In-Vivo Gene Medicine 187

BioPharma Reporter

JUNE 13, 2023

Sygnature Discovery has launched an in vivo inflammation model, that the company says is âexciting but only the beginningâ of understanding life-limiting neuroinflammatory conditions.

In-Vivo 52

In-Vivo Development 52

Bio Pharma Dive

OCTOBER 23, 2023

since late last year as the FDA sought more details on Verve’s in vivo treatment for heart disease. The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S.

In-Vivo 342

In-Vivo Trials 342

Scienmag

SEPTEMBER 28, 2020

CIC biomaGUNE researchers have demonstrated the restoring in vivo of the connection between neurons, yielding functional results Credit: Author: Pedro Ramos / CIC biomaGUNE Research conducted by two groups at the Center for Cooperative Research in Biomaterials CIC biomaGUNE and one at SISSA, Scuola Internazionale Superiore di Studi Avanzati (Italy), (..)

In-Vivo 96

In-Vivo Research Engineer Medicine 96

XTalks

OCTOBER 20, 2023

Intellia said NTLA-2001 is the first investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. As an in vivo therapy, it can edit genes inside the body rather than in cells extracted from patients. ATTR amyloidosis is a rare, progressive and fatal disease.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

pharmaphorum

MAY 26, 2023

Virtual workshop - Unveiling the Potency-Efficacy Connection: Integrating Functional Assay Readouts for In Vivo Insights Mike.Hammerton Fri, 05/26/2023 - 14:00 Bookmark this

In-Vivo 52

In-Vivo 52

Bio Pharma Dive

MARCH 14, 2024

The Swedish biotech will use the investment to advance a kind of personalized cancer therapy that reprograms tumor cells inside the body.

In-Vivo 133

In-Vivo 133

pharmaphorum

JUNE 28, 2021

So far, human trial data for gene-editing drugs have been generated for ex vivo therapies, meaning the CRISPR technology is used to modify cells outside the body, which are then reinfused into the patient. — Eric Topol (@EricTopol) June 26, 2021. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105

In-Vivo Gene Editing Trials Drugs 105

Pharmaceutical Technology

MARCH 21, 2024

Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.

In-Vivo 245

In-Vivo 245

Bio Pharma Dive

OCTOBER 3, 2023

The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.

Gene Editing 260

Gene Editing In-Vivo Gene Genetics 260

BioTech 365

NOVEMBER 9, 2020

LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo London, 9 November 2020 ­–LIfT BioSciences, a biotech company developing (..)

In-Vivo 52

In-Vivo Development 52

Bio Pharma Dive

JULY 17, 2023

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

Gene Editing 237

Gene Editing Gene In-Vivo Research 237

Pharmaceutical Technology

JULY 18, 2023

Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.

Genetics 246

Genetics In-Vivo Development Genome 246

Bio Pharma Dive

JANUARY 31, 2023

The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.

Gene 297

Gene In-Vivo Gene Therapy Manufacturing 297

Scienmag

AUGUST 12, 2020

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72

In-Vivo Research Engineer Medicine 72

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 259

Gene Editing Gene In-Vivo RNA 259

Bio Pharma Dive

NOVEMBER 29, 2022

In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T.

In-Vivo 240

In-Vivo RNA Research Medicine 240

Pharmaceutical Technology

APRIL 26, 2024

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Gene Editing 130

Gene Editing Gene In-Vivo Development 130

Bio Pharma Dive

NOVEMBER 11, 2020

The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology.

In-Vivo 364

In-Vivo Medicine 364

BioTech 365

OCTOBER 25, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report.Intellia, LogicBio fuel hope for in vivo gene editing with new … Continue reading →

Gene Editing 40

Gene Editing In-Vivo Gene Research 40

BioTech 365

AUGUST 25, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 DURHAM, N.C.–(BUSINESS –(BUSINESS WIRE)–Precision BioSciences, Inc.

Gene Editing 40

Gene Editing In-Vivo Gene 40

Bio Pharma Dive

OCTOBER 25, 2023

The study results, while only from three participants, offer a glimpse at how one of the few in vivo CRISPR therapies in U.S. human testing is working.

Gene Editing 154

Gene Editing In-Vivo Gene 154

Scienmag

SEPTEMBER 29, 2021

Furthermore, the current understanding of beta cell function is mostly derived from studies of ex vivo isolated islets in rodent […]. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Development Regulation 52

BioTech 365

MAY 26, 2021

Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The (..)

In-Vivo 40

In-Vivo Marketing 40

BioTech 365

DECEMBER 3, 2021

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting – Upregulation of SCN1A … Continue reading →

In-Vivo 52

In-Vivo 52

BioTech 365

APRIL 8, 2021

Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS

In-Vivo 52

In-Vivo Medicine 52

BioTech 365

DECEMBER 23, 2021

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Orthogonal IL-2 … Continue reading →

In-Vivo 52

In-Vivo 52

BioTech 365

AUGUST 31, 2021

Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit CSO, Cecile … Continue reading →

In-Vivo 52

In-Vivo Gene 52

Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro In-Vivo Genetic Disease Genetics 98

BioTech 365

JANUARY 10, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a … Continue reading →

In-Vivo 52

In-Vivo Research 52

BioTech 365

APRIL 10, 2021

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types … Continue reading →

In-Vivo 40

In-Vivo 40

BioTech 365

APRIL 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi pays $160M for mRNA tech to reprogram T cells in vivo.Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 – … Continue reading →

In-Vivo 40

In-Vivo Research 40

BioTech 365

APRIL 28, 2021

CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of … Continue reading →

In-Vivo 52

In-Vivo 52

BioTech 365

DECEMBER 15, 2020

Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares … Continue reading →

In-Vivo 40

In-Vivo 40